Minerva Neurosciences (NERV) Competitors $2.31 -0.07 (-2.94%) Closing price 01/31/2025 03:55 PM EasternExtended Trading$2.34 +0.03 (+1.47%) As of 01/31/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends NERV vs. OPTN, IOBT, VHAQ, PRLD, KRON, ZIVO, RVPH, PEPG, HOWL, and GBIOShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include OptiNose (OPTN), IO Biotech (IOBT), Viveon Health Acquisition (VHAQ), Prelude Therapeutics (PRLD), Kronos Bio (KRON), ZIVO Bioscience (ZIVO), Reviva Pharmaceuticals (RVPH), PepGen (PEPG), Werewolf Therapeutics (HOWL), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. OptiNose IO Biotech Viveon Health Acquisition Prelude Therapeutics Kronos Bio ZIVO Bioscience Reviva Pharmaceuticals PepGen Werewolf Therapeutics Generation Bio Minerva Neurosciences (NASDAQ:NERV) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Do institutionals and insiders believe in NERV or OPTN? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 2.3% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, NERV or OPTN? Minerva Neurosciences has higher earnings, but lower revenue than OptiNose. Minerva Neurosciences is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M-$0.44-5.25OptiNose$70.99M0.84-$35.48M-$4.20-1.41 Does the MarketBeat Community prefer NERV or OPTN? Minerva Neurosciences received 98 more outperform votes than OptiNose when rated by MarketBeat users. However, 63.68% of users gave OptiNose an outperform vote while only 57.07% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34757.07% Underperform Votes26142.93% OptiNoseOutperform Votes24963.68% Underperform Votes14236.32% Does the media prefer NERV or OPTN? In the previous week, Minerva Neurosciences and Minerva Neurosciences both had 3 articles in the media. OptiNose's average media sentiment score of 1.61 beat Minerva Neurosciences' score of 0.29 indicating that OptiNose is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OptiNose 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is NERV or OPTN more profitable? Minerva Neurosciences has a net margin of 0.00% compared to OptiNose's net margin of -41.16%. Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% OptiNose -41.16%N/A -27.42% Do analysts prefer NERV or OPTN? Minerva Neurosciences currently has a consensus price target of $5.00, suggesting a potential upside of 116.45%. OptiNose has a consensus price target of $16.67, suggesting a potential upside of 181.53%. Given OptiNose's stronger consensus rating and higher probable upside, analysts clearly believe OptiNose is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00OptiNose 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, NERV or OPTN? Minerva Neurosciences has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. SummaryOptiNose beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.16M$6.87B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-5.257.6680.0317.24Price / SalesN/A320.221,259.7283.26Price / CashN/A73.5045.9637.70Price / Book-0.575.275.124.70Net Income-$30M$136.98M$111.40M$224.47M7 Day Performance5.48%-0.84%2.30%-0.19%1 Month Performance4.05%-0.02%3.13%0.57%1 Year Performance-73.29%7.51%24.60%20.35% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.4961 of 5 stars$2.31-2.9%$5.00+116.5%-72.7%$16.16MN/A-5.259Analyst ForecastShort Interest ↑OPTNOptiNose4.6131 of 5 stars$6.39-2.4%$16.67+160.8%-68.7%$64.28M$70.99M-1.52190Short Interest ↓IOBTIO Biotech3.7761 of 5 stars$0.96+1.4%$9.33+874.3%-48.3%$63.11MN/A-0.7030Short Interest ↓Gap UpHigh Trading VolumeVHAQViveon Health AcquisitionN/A$11.00flatN/A-2.3%$62.26MN/A0.002PRLDPrelude Therapeutics3.662 of 5 stars$1.13-7.0%$4.00+254.0%-66.5%$62.18MN/A-0.63120KRONKronos Bio3.6169 of 5 stars$1.03-1.4%$1.63+58.5%-10.6%$61.85M$6.29M-0.72100Short Interest ↑Positive NewsZIVOZIVO BioscienceN/A$17.00-9.9%N/A+142.7%$61.54M$30,000.00-3.4810High Trading VolumeRVPHReviva Pharmaceuticals4.3504 of 5 stars$1.82-4.7%$11.40+526.4%-51.3%$60.86MN/A-1.645Short Interest ↓PEPGPepGen2.6573 of 5 stars$1.86-4.1%$13.67+634.8%-87.1%$60.63MN/A-0.6230Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap UpHOWLWerewolf Therapeutics3.0531 of 5 stars$1.35-2.2%$9.33+591.4%-71.1%$60.16M$3.39M-0.8840Short Interest ↑Gap UpGBIOGeneration Bio3.6606 of 5 stars$0.89-5.1%$6.50+630.8%-58.5%$59.40M$5.90M-0.41150Short Interest ↑ Related Companies and Tools Related Companies OptiNose Alternatives IO Biotech Alternatives Viveon Health Acquisition Alternatives Prelude Therapeutics Alternatives Kronos Bio Alternatives ZIVO Bioscience Alternatives Reviva Pharmaceuticals Alternatives PepGen Alternatives Werewolf Therapeutics Alternatives Generation Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NERV) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NERV Stock Alerts